/Investor DB

Vsquared Ventures — 2025 Investments

4 investments dated 2025 · listed companies and verified rows first · show all

Atrandi Biosciencesatrandi.cominSeries A · Feb 2025 · $25M

Atrandi makes Flux, a device that isolates thousands to hundreds of thousands of individual cells simultaneously into semi-permeable capsules for downstream genomic and microbial analysis.

AI & Machine LearningBiotechDeep TechHardwareVilnius, LT

Co-investorsGRIDS CapitalLux CapitalMetaplanetPractica Capital

Belfortbelfortlabs.comin𝕏Sep 2025 · $6M

Belfort develops hardware and algorithms to accelerate encrypted computation, including Fully Homomorphic Encryption, so sensitive data can be processed without being decrypted.

CybersecurityDeep TechHardware

Michiel Van Beirendonck(Principal Architect / Co-founder)inLaurens De Poorter(Co-founder)in

Co-investorsSyndicate OneAnagram VenturesCredibly NeutralInovia Capital

Hederahederadx.comin𝕏Series A · May 2025 · $17M

Hedera Dx develops in-house, NGS-based liquid biopsy tests and clinicogenomic data solutions for decentralized oncology care, partnering with laboratories and clinicians to support cancer diagnosis and personalized therapy selection.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Tommi Lehtonen(CEO, Co-founder)inDamien Lapray(CCO, Co-founder, PhD)inChristian Meisel(CMO, Co-founder, MD PhD)inFrances Rhodius(CFO)

Co-investorsAmino CollectiveBootstrap EuropeHelsana HealthInvest AGInventureInventureTesi (Finnish Industry Investment Ltd)

Safe Intelligencesafeintelligence.aiin𝕏Feb 2025

Safe Intelligence provides a software platform, tooling, and services that use formal verification, testing, and robust learning to validate and harden machine learning models such as neural networks and tree ensembles.

AI & Machine LearningCybersecurityDeep TechDeveloper Tools

Steven Willmott(CEO)inAlessio Lomuscio(CTO)in

Co-investorsAmadeus Capital PartnersOTB Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.